Alzamend Neuro Inc. (NASDAQ: ALZN) Targets Transformative Mental Health Breakthroughs
Alzamend Neuro tackles Alzheimer’s, BD, MDD and PTSD with breakthrough therapies. AL001 delivers improved brain targeting and fewer side effects than lithium carbonate. Phase II trials underway with support from Mass General and AI partner QMENTA. ALZN002 offers a novel, adjuvant-free immunotherapy for Alzheimer’s disease. Alzamend Neuro (NASDAQ: ALZN) is a clinical-stage biopharmaceutical company tackling some of the most pressing neurological and psychiatric conditions of our time — including Alzheimer’s disease, Bipolar Disorder (BD), Major Depressive Disorder (MDD), and Post-Traumatic Stress Disorder (PTSD). With a mission to “Make Alzheimer’s Just a Memory™,” the Atlanta-based company is advancing a robust pipeline of…
